MOTS-c for Sale: Which Listing Claims Are Testable

MOTS-c for sale comes in three formats, and they are not interchangeable presentations of the same thing. Each one changes what a certificate of analysis can tell you, and one of them removes the certificate's meaning entirely.

What follows sorts the standard vocabulary of these listings into claims that point at a document and claims that point at nothing. The test throughout is the same: if this sentence were false, what record would reveal it?

MOTS-c for sale: three formats and what each costs you analytically

The lyophilised single-peptide vial is the only format in which the standard analytical package means what it appears to mean. Dry powder can be weighed, dissolved under controlled conditions, run on HPLC, measured by mass spectrometry, and titrated for water, and every one of those results describes the material in the vial.

A blend breaks the interpretation of a single purity figure. A solution breaks the link between the certificate and what is being sold. Neither is necessarily fraudulent. Both transfer verification work from the seller to a buyer who cannot perform it.

One structural feature of this market is worth stating early, because it changes how the listings compare. MOTS-c is sold almost universally as a single 10 mg presentation, so there is no larger vial to weigh against a smaller one and no per-milligram advantage available by moving up a size. The only second dimension is quantity. That narrows the comparison usefully: with format and strength effectively fixed across sellers, what remains to distinguish one listing from another is the analytical record behind it and the terms attached to it, which is the whole of what follows.

Listing claims and the record that would settle each one

Note what the middle column is not. None of these records prove the material is good. They make the claim checkable, which is a weaker property and the only one available to a buyer reading a page.

Purity tiers: why a percentage is not a grade

Sellers frequently offer the same peptide at two purity levels with a price difference attached. The implicit claim is that the higher figure describes better material. It might do. The number by itself cannot establish it.

HPLC purity is the area under the main peak divided by the total integrated area, at a stated detection wavelength, normally 214 nm for peptides because the amide backbone absorbs there. That makes the result relative and sensitive to method: the gradient, the run length, and the threshold below which small peaks are ignored all move it. ICH Q2(R2) treats the method description as part of the result for exactly this reason, and two honest laboratories can report figures a point apart on one vial.

So a tier is analytical only when the higher tier comes with a visibly different chromatogram: fewer peaks, a cleaner region beside the main peak, a smaller shoulder. On a 16-residue synthetic peptide, that shoulder is usually a deletion sequence one residue short, and it is the impurity a percentage is least able to describe. Anyone comparing MOTS-c peptides for sale across suppliers is comparing method choices as much as material until the traces are on screen together.

Blends and mitochondrial stacks: two peptides, one chromatogram

Combination vials are marketed as convenience and sold at a premium. Analytically they create a problem that most blend certificates do not address. A chromatogram of a two-component blend has two main peaks, so an area percentage no longer answers how much of this is the peptide, and it certainly does not report the ratio between the components.

A blend certificate has to do two things a single-peptide certificate does not: state the content of each component separately, and identify each by measured mass. Without both, the vial contains an unknown split of two substances, and a buyer cannot even work out the cost per milligram of either. That is before considering whether the two peptides are stable in one lyophilised cake, which is a question nobody in this market publishes stability data on.

Pre-mixed solutions: the format that defeats its own certificate

A ready-to-use solution is the format that should end the evaluation. The certificate, when one exists, was issued on the lyophilised powder before dilution, so it describes a material that is no longer what is being sold. Nobody independent witnessed the dilution, so the stated concentration rests entirely on the seller's arithmetic.

The chemistry is against the format too. Water content cannot be determined by Karl Fischer titration on an aqueous solution, so one standard check disappears. Peptides in solution degrade considerably faster than dry powder, and this sequence carries two methionines, which gives oxidation a ready route. If a preservative has been added, that is a further component with its own stability behaviour and no disclosure. Buyers looking at MOTS-c peptide for sale in liquid form are paying a premium to remove every check the dry format allows.

What a listing has to disclose to be checkable

Six disclosures make a listing examinable: the lot number of material in stock, the analysing laboratory, the analysis date, the HPLC trace with its wavelength, a measured mass beside the theoretical mass, and the salt form with a water figure. Listings meeting all six are a minority.

The salt form is the disclosure most often missing and the one with the largest arithmetic consequence. Material isolated as a trifluoroacetate salt can carry several TFA equivalents on a sequence with three arginines, one lysine, and a free N-terminal amine, and at three equivalents roughly 14 percent of the labelled mass is counterion rather than peptide. Residual trifluoroacetate is not inert either: it has been shown to inhibit proliferation in osteoblast and chondrocyte culture, which matters directly to cell work.

Against those six, the offer on this page is a single lyophilised 10 mg presentation at $75.00, reduced to $37.50 by the code PEPTIDEDECK, with certificates published from two laboratories per lot, Kovera Labs on batch #24-05260628 and MZ Biolabs on batch #24-01260229. Those are the vendor's own published records and this site earns a commission on sales, which is precisely why the case is stated as documents you can open rather than as a recommendation. The criteria in full are in our supplier verification guide, and the channel comparison sits in where to buy MOTS-c.

What is not for sale: the clinical evidence

Every listing in this market sells material. None of them sells evidence, and the evidence for MOTS-c is preclinical almost in its entirety. Lee and colleagues characterised the peptide in Cell Metabolism in 2015 as a mitochondrial-derived regulator of metabolic homeostasis acting through AMPK, in cell culture and in mice, and the 2016 review by Lee, Kim, and Cohen summarises the muscle and fat work that followed on the same footing.

The single human clinical programme belonged to CB4211, an analogue rather than MOTS-c, which completed a Phase 1a/1b study of 88 participants (NCT03998514) in April 2021 before its sponsor wound down. No Phase 3 programme exists and no large human efficacy trial has been run. A listing cannot change that, and a listing that implies otherwise has failed the last check on this page. For how those distinctions are drawn, see trial phases explained.